Verastem Oncology announced that Channing Der has been appointed to its Scientific Advisory Board. Dr. Der, a preeminent researcher in the science of RAS pathway signaling and rational drug combinations, will provide expert guidance as Verastem advances its work in RAS pathway-driven cancers, including lead compound, RAF/MEK clamp VS-6766. Dr. Der is the Sarah Graham Kenan Distinguished Professor at the University of North Carolina at Chapel Hill.

Since his initial discovery of RAS oncogenes in human cancer in the early 1980s, his research has centered on the study of RAS and RHO oncoproteins in cancer.